[{"indications": "Indications\u00a0prevention of nephrotoxicity associated with cidofovir (section 5.3.2.2)", "name": "PROBENECID", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.4 Gout and cytotoxic-induced hyperuricaemia", "Long-term control of gout", "PROBENECID"], "cautions": "Cautions\u00a0ensure adequate fluid intake (about 2\u20133 litres\r\ndaily) and render urine alkaline if uric\r\nacid overload is high; peptic ulceration; transient false-positive Benedict\u2019s test; G6PD-deficiency (section 9.1.5); interactions: Appendix 1\r\n(probenecid)", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances; less commonly sore gums, flushing, headache, dizziness, urinary frequency, anaemia,\r\nalopecia; hepatic necrosis, hypersensitivity reactions (including\r\nanaphylaxis, pruritus, urticaria, fever, and Stevens-Johnson syndrome),\r\nnephrotic syndrome, haemolytic anaemia, leucopenia, and aplastic anaemia\r\nalso reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5319.htm", "doses": ["Used with cidofovir, see section 5.3.2.2"]}]